Investor Relations

Investors

Investor Relations

Corporate Profile

Anpac Bio is a biotechnology company focusing on early cancer screening and detection and marketing a suite of cancer detection tests, including CDA (cancer differentiation analysis), bio-chemistry, immunology, and genomics tests. Anpac has developed a multi-cancer screening and detection test that uses innovative, patented CDA technology and proprietary cancer-detection device.

Press Releases

May 26, 2020

AnPac Bio Continues to Build Strong Patent Portfolio, with 3rd Patent Granted This Year in the United States

SAN JOSE, Calif., May 26, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that another new US

May 18, 2020

AnPac Files Its Annual Report on Form 20-F

SAN JOSE, Calif., May 18, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it has filed its annual

May 11, 2020

AnPac Bio Granted New Patent in Novel Medical Device for Disease Detection in the United States

SAN JOSE, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today the allowance by the

Stock Quote

Change

Volume

52 Week High

52 Week Low

May 29, 2020 10:49 PM EDT

Events

More events are coming soon.

Investors

Investor Relations

Corporate Profile

Stock Quote

Quick Links

Contact Information